liu.seSök publikationer i DiVA
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Improved outcome from substituting methotrexate with epirubicin: Results from a randomised comparison of CMF versus CEF in patients with primary breast cancer
Department of Oncology, Copenhagen University Hospital, Bldg. 5012, Rigshospitalet, 9. Blegdamsvej, DK-2100 Copenhagen, Denmark.
Department of Oncology, Copenhagen University Hospital, Bldg. 5012, Rigshospitalet, 9. Blegdamsvej, DK-2100 Copenhagen, Denmark, DBCG Registry, Copenhagen, Denmark.
DBCG Registry, Copenhagen, Denmark.
Department of Oncology, Aarhus Hospital, Aarhus University, Denmark.
Visa övriga samt affilieringar
2007 (Engelska)Ingår i: European Journal of Cancer, ISSN 0959-8049, E-ISSN 1879-0852, Vol. 43, nr 5, s. 877-884Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

We compared the efficacy of CEF (cyclophosphamide, epirubicin, and fluorouracil) against CMF (cyclophosphamide, methotrexate, and fluorouracil) in moderate or high risk breast cancer patients. We randomly assigned 1224 patients with completely resected unilateral breast cancer to receive nine cycles of three-weekly intravenous CMF or CEF. Patients were encouraged to take part in a parallel trial comparing oral pamidronate 150 mg twice daily for 4 years versus control (data not shown). Substitution of methotrexate with epirubicin significantly reduced the unadjusted hazard for disease-free survival (DFS) by 16% (hazard ratio 0.84, 95% CI, 0.71-0.99) and for overall survival by 21% (hazard ratio 0.79, 95% CI, 0.66-0.94). The risk of secondary leukaemia and congestive heart failure was similar in the two groups. Overall CEF was superior over CMF in terms of DFS and OS in patients with operable breast cancer without subsequent increase in late toxicities. © 2007 Elsevier Ltd. All rights reserved.

Ort, förlag, år, upplaga, sidor
2007. Vol. 43, nr 5, s. 877-884
Nyckelord [en]
Antineoplastic combined chemotherapy protocols, Breast neoplasms, Cyclophosphamide, Epirubicin, Fluorouracil, Methotrexate, Proportional hazards models, Randomised controlled trials, Survival analysis
Nationell ämneskategori
Medicin och hälsovetenskap
Identifikatorer
URN: urn:nbn:se:liu:diva-49977DOI: 10.1016/j.ejca.2007.01.009OAI: oai:DiVA.org:liu-49977DiVA, id: diva2:270873
Tillgänglig från: 2009-10-11 Skapad: 2009-10-11 Senast uppdaterad: 2017-12-12

Open Access i DiVA

Fulltext saknas i DiVA

Övriga länkar

Förlagets fulltext

Personposter BETA

Nordenskjöld, Bo

Sök vidare i DiVA

Av författaren/redaktören
Nordenskjöld, Bo
Av organisationen
HälsouniversitetetOnkologiOnkologiska kliniken US
I samma tidskrift
European Journal of Cancer
Medicin och hälsovetenskap

Sök vidare utanför DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetricpoäng

doi
urn-nbn
Totalt: 53 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf